Curis Lifesciences IPO

About the company

Curis Lifesciences Limited is engaged in manufacturing pharmaceutical products such as tablets, capsules, external preparations, oral liquid, sterile ophthalmic ointments. The company’s business model involves the following main activities: loan license manufacturing, contract manufacturing and direct exports. It has served 100+ customers for loan licensing and contract manufacturing, and 2 customers for direct exports/own brand marketing, primarily in Yemen and Kenya. Product wise, major revenue contribution came from tablets, accounting for 87.90% of revenue. Loan license manufacturing contributed 0.98%, contract manufacturing for merchant exports 55.62% and domestic suppliers 43.40% as of July, 2025.

Financial performance (₹ Cr)

Subscription breakup (final, times)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   07 Nov 2025

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   11 Nov 2025

   Last day to place your bid

3. Basis of Allotment

   Completed
   12 Nov 2025

   Share allotment finalised

4. Refund Initiation

   Completed
   13 Nov 2025

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   13 Nov 2025

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   14 Nov 2025

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.